DPP-IV is an enzyme responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)
doi: 10.1016/S0140-6736(19)32517-6 Summary Keywords non-alcoholic steatohepatitis, nonalcoholic fatty liver disease, obesity, insulin resistance, metabolic syndrome, metabolic disease, fibroblast growth factor 21 Citation Tillman EJ and Rolph T (2020) FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases
The percentage of patients diagnosed with thyroid cancer was 0.23% in the DPP4i group, 0.17% in the GLP-1RA group, 0.17% in the SGLT2i group, and 0.20% in the SU group
Real needle-free options exist: the Wegovy oral tablet (FDA-approved December 2025) and experimental microneedle patches in early clinical trials
Sermorelin addresses this by stimulating the pituitary gland, helping to restore your energy, vitality, and physical performance